Risk of Cardiovascular Events and Celecoxib: a Systematic Review and Meta-Analysis

Caldwell, Brent; Aldington, Sarah; Weatherall, Mark; Shirtcliffe, Philippa; Beasley, Richard

doi:10.1177/014107680609900315

Cited by 106 publications

(50 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, uncertainty remains about the nature of such risks as well as the relative safety of NSAIDs (Bhala et al 2013;Caldwell et al 2006;Chen et al 2008;Henry 2006, 2011;Salvo et al 2011;Trelle et al 2011). Our analysis agrees with the limited number of studies that have looked for, and found, that NSAIDs are not only heterogeneous in their extent of CV/renal risks but also differ in the nature of their adverse effects on different body systems.…”

Section: Discussionmentioning

confidence: 99%

“…It is well established that inflammatory conditions, in general, and arthritis, in particular, are associated with increased morbidity and mortality mainly due to CV complications (Jamali 2007). In addition, since emphasis is usually given to the composite CV/renal risk, the nature of the adverse effects of NSAIDs (e.g., myocardial, vascular and renal) have remained mainly unknown (Caldwell et al 2006;Juni et al 2004). A differentiation between these outcomes is essential as not all NSAIDs carry the same potential of influencing a particular system in the body.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review

Asghar

Jamali

2014

Inflammopharmacol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review

Asghar

Jamali

2014

Inflammopharmacol

View full text Add to dashboard Cite

show abstract

“…A concern that has arisen lately regarding the use of COX-2 inhibitors is the increasing risk of cardiovascular diseases, as shown in a few meta-analysis assessing the risk of MI with selective COX-2 inhibitors including celecoxib [163][164][165][166]. For that reason, cautious use may have to be considered in high risk patients for cardiovascular disease.…”

Section: Celecoxibmentioning

confidence: 99%

Pancreatic cancer: from molecular pathogenesis to targeted therapy

Strimpakos

Saif

Syrigos

2008

Cancer Metastasis Rev

View full text Add to dashboard Cite

Pancreatic cancer is a deadly malignancy with still high mortality and poor survival despite the significant advances in understanding, diagnosis, and access to conventional and novel treatments. Though cytotoxic chemotherapy based on the purine analogue gemcitabine remains the standard approach in adjuvant and palliative setting the need for novel agents aiming at the main pathophysiological abnormalities and molecular pathways involved remains soaring. So far, evidence of clinical benefit, though small, exists only from the addition of the targeted agent erlotinib on the standard gemcitabine chemotherapy. Apart from the popular monoclonal antibodies and small molecules tyrosine kinase inhibitors, other novel compounds being tested in preclinical and clinical studies target mTOR, NF-kappaB, proteasome and histone deacetylase. These new drugs along with gene therapy and immunotherapy, which are also under clinical evaluation, may alter the unfavorable natural course of this disease. In this review we present the main pathophysiological alterations met in pancreatic cancer and the results of the florid preclinical and clinical research with regards to the targeted therapy associated to these abnormalities.

show abstract

“…Cyclooxygenase-2 (COX-2) inhibitor use is associated with adverse side effects, including gastrointestinal complications and increased risk of myocardial infarction [3]. Although effective in the short-term, multiple corticosteroid injections in a joint and prolonged exposure to steroids can harm articular cartilage and accelerate progression of OA [4].…”

Section: Introductionmentioning

confidence: 99%

Cell Therapy for Knee Osteoarthritis: Mesenchymal Stromal Cells

Kim

Keating

2019

Gerontology

View full text Add to dashboard Cite

Osteoarthritis (OA) is designated the 11th highest contributor of 291 diseases of global disability and the most common cause of chronic disability in elderly people. OA has a devastating impact on quality of life and represents an enormous socio-economic burden. Currently, OA is incurable, and no approved medications, biological therapy, or procedure prevents the progressive destruction of the osteoarthritic knee joint. All current treatments provide symptomatic relief rather than preventative or regenerative results. There is an urgent and compelling need to find, validate, and test new biological therapeutics. Cell-based therapies involving the delivery of mesenchymal stromal cells (MSCs) to the osteoarthritic knee joint have emerged as a potential solution to overcome this clinical shortcoming. In this review, we address the clinical evidence, challenges, and recent advances surrounding MSC treatment in knee OA.

show abstract

Risk of Cardiovascular Events and Celecoxib: a Systematic Review and Meta-Analysis

Abstract: The available data indicate an increased risk of myocardial infarction with celecoxib therapy, consistent with a class effect for COX-2 specific inhibitors.

Cited by 106 publications

References 31 publications

The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review

The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review

Pancreatic cancer: from molecular pathogenesis to targeted therapy

Cell Therapy for Knee Osteoarthritis: Mesenchymal Stromal Cells

Contact Info

Product

Resources

About